Journal Mobile Options
Table of Contents
Vol. 24, No. 1, 2002
Issue release date: January–February (July 2002)

Multiple Actions of Pituitary Adenylyl Cyclase Activating Peptide in Nervous System Development and Regeneration

Waschek J.A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Pituitary adenylyl cyclase activating peptide (PACAP) is widely expressed in the embryonic brain at the onset of neurogenesis, and is strongly upregulated in several models of nerve injury. Moreover, high-affinity PACAP receptors are expressed in proliferative zones in the embryonic and postnatal nervous system suggesting that PACAP regulates the development of both neuronal and glial precursors. Tissue culture studies indicate that PACAP exerts a variety of growth factor-like actions that depend on the origin of the cell population and developmental stage. These effects include regulation of proliferation, survival, maturation, neurite outgrowth, and expression of trophic factors, cytokines and trk receptors. The presence of other growth factors can also markedly affect these actions of PACAP, for example, reversing PACAP’s effect from proliferative to antiproliferative. In vivo models now provide additional evidence that PACAP acts in neural development and regeneration.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H: Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev 2000;52:269–324.
  2. Waschek JA: Vasoactive intestinal peptide: An important trophic factor and developmental regulator? Dev Neurosci 1995;17:1–7.

    External Resources

  3. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S: Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811–819.

    External Resources

  4. Lutz EM, Sheward WJ, West JM, Morrow JA, Fink G, Harmar AJ: The VIP2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993;334:3–8.
  5. Pisegna JR, Wank SA: Molecular cloning and functional expression of the pituitary adenylate-activating polypeptide type I receptor. Proc Natl Acad Sci USA 1993;90:6345–6349.

    External Resources

  6. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L: Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993;365:170–175.
  7. Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J, Spengler D: Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. Biochem Soc Trans 1995;23:133–137.
  8. Pisegna JR, Wank SA: Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. J Biol Chem 1996;271:17267–17274.
  9. Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J, Journot L: Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem 1996;271:22146–22151.
  10. Chatterjee TK, Sharma RV, Fisher RA: Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 1996;271:32226–32232.
  11. Murthy KS, Zhang K-M, Jin J-G: VIP-mediated G protein-coupled Ca2+ influx activates a constitutive NOS in dispersed gastric muscle cells. Am J Physiol 1993;265:G600–G671.
  12. Morisset J, Douziech N, Rydzewska G, Buscail L, Rivard N: Cell signalling pathway involved in PACAP-induced AR4-2J cell proliferation. Cell Signal 1995;7:195–205.
  13. Straub SG, Sharp GW: A wortmannin-sensitive signal transduction pathway involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. J Biol Chem 1996;271:1660–1668.
  14. Koh SW: Signal transduction through the vasoactive intestinal peptide receptor stimulates phosphorylation of the kinase pp60c-Src. Biochem Biophys Res Commun 1991;174:452–458.

    External Resources

  15. Villalba M, Bockaert J, Journot L: Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 1997;17:83–90.
  16. Barrie AF, Clohessy AM, Buensuceso CS, Rogers MV, Allen JM: Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in ras-independent, mitogen-activated protein kinase/ERK kinase 1- or 2-dependent manner in PC12 cells. J Biol Chem 1997;272:19666–19671.
  17. Lelièvre V, Pineau N, Du J, Wen C-H, Nguyen TB, Janet J, Muller J-M, Waschek JA: Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression on neuroblastoma cell proliferation: A novel VIP-independent action of PHI via MAPkinase. J Biol Chem 1998;273:19685–19690.
  18. Tatsuno I, Somogyvari-Vigh A, Arimura A: Developmental changes of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor in the rat brain. Peptides 1994;15:55–60.
  19. Basille M, Gonzalez BJ, Leroux P, Jeandel L, Fournier A, Vaudry H: Localization and characterization of PACAP receptors in the rat cerebellum during development: Evidence for a stimulatory effect of PACAP on immature cerebellar granule cells. Neuroscience 1993;57:329–338.
  20. Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI: Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: Potential role in patterning and neurogenesis. Proc Natl Acad Sci USA 1998;95:9602–9607.
  21. Sheward WJ, Lutz EM, Copp AJ, Harmar AJ: Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Dev Brain Res 1998;109:245–253.

    External Resources

  22. Sheward WJ, Lutz EM, Harmar AJ: Expression of pituitary adenylate cyclase activating polypeptide receptors in the early mouse embryo as assessed by reverse transcription polymerase chain reaction and in situ hybridisation. Neurosci Lett 1996;216:45–48.
  23. Shuto Y, Uchida D, Onda H, Arimura A: Ontogeny of pituitary adenylate cyclase activating polypeptide and its receptor mRNA in the mouse brain. Regul Pept 1996;67:79–83.
  24. Zhou CJ, Shioda S, Shibanuma M, Nakajo S, Funahashi H, Nakai Y, Arimura A, Kikuyama S: Pituitary adenylate cyclase-activating polypeptide receptors during development: Expression in the rat embryo at primitive streak stage. Neuroscience 1999;93:375–391.
  25. Zhou C, Kikuyama S, Nakajo S, Hirabayashi T, Mizushima H, Shioda S: Splice variants of PAC(1) receptor during early neural development of rats. Peptides 2000;21:1177–1183.

    External Resources

  26. Zhou CJ, Yada T, Kohno D, Kikuyama S, Suzuki R, Mizushima H, Shioda S: PACAP activates PKA, PKC and Ca(2+) signaling cascades in rat neuroepithelial cells. Peptides 2001;22:1111–1117.

    External Resources

  27. Basille M, Vaudry D, Coulouarn Y, Jegou S, Lihrmann I, Fournier A, Vaudry H, Gonzalez B: Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J Comp Neurol 2000;425:495–509.
  28. Lee M, Lelièvre V, Zhao P, Torres M, Rodriguez W, Byun JY, Doshi S, Ioffe Y, Gupta G, de los Monteros AE, de Vellis J, Waschek J: Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors. J Neurosci 2001;21:3849–3859.

    External Resources

  29. Lelièvre V, Hu Z, Byun J-B, Ioffe Y, Waschek J: FGF-2 converts PACAP growth action on embryonic hindbrain precursors from stimulation to inhibition. J Neurosci Res 2002;67:566–573.
  30. DiCicco-Bloom E, Deutsch PJ, Maltzman J, Zhang J, Pintar JE, Zheng J, Friedman WF, Zhou X, Zaremba T: Autocrine expression and ontogenetic functions of the PACAP ligand/receptor system during sympathetic development. Dev Biol 2000;219:197–213.
  31. Lu N, DiCicco-Bloom E: Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc Natl Acad Sci USA 1997;94:3357–3362.
  32. Frechilla D, Garcia-Osta A, Palacios S, Cenarruzabeitia E, Del Rio J: BDNF mediates the neuroprotective effects of PACAP-38 on rat cortical neurons. Neuroreport 2001;12:919–923.

    External Resources

  33. Pellegri G, Magistretti PJ, Martin JL: VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci 1998;10:272–280.

    External Resources

  34. Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H: Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 1997;78:419–430.

    External Resources

  35. Villalba M, Bockaert J, Journot L: Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 1997;17:83–90.
  36. Chang JY, Korolev VV, Wang JZ: Cyclic AMP and pituitary adenylate cyclase-activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells. Neurosci Lett 1996;206:181–184.
  37. Cavallaro S, Copani A, D’Agata V, Musco S, Petralia S, Ventra C, Stivala F, Travali S, Canonico PL: Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 1996;50:60–66.
  38. Kienlen Campard P, Crochemore C, Rene F, Monnier D, Koch B, Loeffler JP: PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA Cell Biol 1997;16:323–333.
  39. Hansel DE, May V, Eipper BA, Ronnett GV: Pituitary adenylyl cyclase-activating peptides and alpha-amidation in olfactory neurogenesis and neuronal survival in vitro. J Neurosci 2001;21:4625–4636.

    External Resources

  40. Lioudyno M, Skoglosa Y, Takei N, Lindholm D: Pituitary adenylate cyclase-activating polypeptide (PACAP) protects dorsal root ganglion neurons from death and induces calcitonin gene-related peptide (CGRP) immunoreactivity in vitro. J Neurosci Res 1998;51:243–256.
  41. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I, Bay V, Brenneman DE: PACAP functions as a neurotrophic factor. Ann NY Acad Sci 1994;739:228–243.
  42. Takei N, Skoglosa Y, Lindholm D: Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergineurons. J Neurosci Res 1998;54:698–706.
  43. Takei N, Torres E, Yuhara A, Jongsma H, Otto C, Korhonen L, Abiru Y, Skoglosa Y, Schutz G, Hatanaka H, Sofroniew MV, Lindholm D: Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: Comparison with effects of nerve growth factor. Eur J Neurosci 2000;12:2273–2280.

    External Resources

  44. Tatsuno I, Morio H, Tanaka T, Uchida D, Hirai A, Tamura Y, Saito Y: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a regulator of astrocytes: PACAP stimulates proliferation and production of interleukin 6 (IL-6), but not nerve growth factor (NGF), in cultured rat astrocyte. Ann NY Acad Sci 1996;805:482–488.
  45. Gottschall PE, Tatsuno I, Arimura A: Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: Synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res 1994;637:197–203.
  46. Kim WK, Kann Y, Ganea D, Hart RP, Gozes I, Jonakait GM: Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci 2000;20:3622–3630.
  47. Pincus DW, DiCicco-Bloom EM, Black IB: Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 1990;343:564–567.
  48. Pincus DW, DiCicco-Bloom EM, Black IB: Trophic mechanisms regulate mitotic neuronal precursors: Role of vasoactive intestinal peptide (VIP). Brain Res 1994;663:51–60.
  49. Lu N, Zhou R, DiCicco-Bloom E: Opposing mitogenic regulation by PACAP in sympathetic and cerebral cortical precursors correlates with differential expression of PACAP receptor (PAC1-R) isoforms. J Neurosci Res 1998;53:651–662.
  50. Suh J, Lu N, Nicot A, Tatsuno I, DiCicco-Bloom E: PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat Neurosci 2001;4:123–124.
  51. Skoglosa Y, Takei N, Lindholm D: Distribution of pituitary adenylate cyclase activating polypeptide mRNA in the developing rat brain. Brain Res Mol Brain Res 1999;65:1–13.
  52. Nielsen HS, Hannibal J, Fahrenkrug J: Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex. Neuroreport 1998;9:2639–2642.

    External Resources

  53. Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H: Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 1998;84:801–812.

    External Resources

  54. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H: The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci USA 2000;97:13390–13395.
  55. DiCicco-Bloom E, Emsb K, Black IB: VIP regulates development of multiple neuronal populations: Sensory and cerebellar granule cells. Soc Neurosci 1992;18:418.
  56. Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H: Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proc Natl Acad Sci USA 1999;96:9415–9420.
  57. Suh J, Lu N, Nicot A, Tatsuno I, DiCicco-Bloom E: PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat Neurosci 2001;4:123–124.
  58. Chang E, Welch S, Luna J, Giacalone J, Francke U: Generation of a human chromosome 18-specific YAC clone collection and mapping of 55 unique YACs by FISH and fingerprinting. Genomics 1993;17:393–402.
  59. Overhauser J, Mitchell HF, Zackai EH, Tick DB, Rojas K, Muenke M: Physical mapping of the holoprosencephaly critical region in 18p11.3. Am J Hum Genet 1995;57:1080–1085.

    External Resources

  60. Mackay M, Fantes J, Scherer S, Boyle S, West K, Tsui LC, Belloni E, Lutz E, Van Heyningen V, Harmar AJ: Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: A possible contributor to the holoprosencephaly 3 phenotype. Genomics 1996;37:345–353.
  61. Przywara DA, Kulkarni JS, Wakade TD, Leontiev DV, Wakade AR: Pituitary adenylyl cyclase-activating polypeptide and nerve growth factor use the proteasome to rescue nerve growth factor-deprived sympathetic neurons cultured from chick embryos. J Neurochem 1998;71:1889–1897.

    External Resources

  62. Zhou X, Rodriguez WI, Casillas RA, Ma V, Tam J, Hu Z, Lelièvre V, Chao A, Waschek JA: Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J Neurosci Res 1999;57:953–961.
  63. Moller K, Reimer M, Ekblad E, Hannibal J, Fahrenkrug J, Kanje M, Sundler F: The effects of axotomy and preganglionic denervation on the expression of pituitary adenylate cyclase activating peptide (PACAP), galanin and PACAP type 1 receptors in the rat superior cervical ganglion. Brain Res 1997;775:166–182.

    External Resources

  64. Zhang YZ, Hannibal J, Zhao Q, Moller K, Danielsen N, Fahrenkrug J, Sundler F: Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: Up-regulation after peripheral nerve injury. Neuroscience 1996;74:1099–1110.
  65. Skoglosa Y, Lewen A, Takei N, Hillered L, Lindholm D: Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: Comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience 1997;90:235–247.
  66. Shin CM, Chung YH, Kim MJ, Cha CI: Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia. Neurosci Lett 2001;309:53–56.

    External Resources

  67. Gillardon F, Hata R, Hossmann KA: Delayed up-regulation of Zac1 and PACAP type I receptor after transient focal cerebral ischemia in mice. Brain Res Mol Brain Res 1998;61:207–210.

    External Resources

  68. Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S, Banks WA: Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 1996;736:280–286.

    External Resources

  69. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A: Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000;31:1411–1417.
  70. Takei N, Torres E, Yuhara A, Jongsma H, Otto C, Korhonen L, Abiru Y, Skoglosa Y, Schutz G, Hatanaka H, Sofroniew MV, Lindholm D: Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo comparison with effects of nerve growth factor. Eur J Neurosci 2000;12:2273–2280.

    External Resources

  71. Morio H, Tatsuno I, Hirai A, Tamura Y, Saito Y: Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res 1996;741:82–88.

    External Resources

  72. Ito Y, Arakawa M, Ishige K, Fukuda H: Comparative study of survival signal withdrawal- and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neurosci Res 1999;35:321–327.
  73. Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL: The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 1996;6:5–27.
  74. Ganea D: Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol 1996;6:61–74.
  75. De la Fuente M, Delgado M, Gomariz RP: VIP modulation of immune cell functions. Adv Neuroimmunol 1996;6:75–91.
  76. Goetzl EJ, Pankhaniya RR, Gaufo GO, Mu Y, Xia M, Sreedharan SP: Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses. Ann NY Acad Sci 1998;840:540–550.


Pay-per-View Options
Direct payment This item at the regular price: USD 9.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 8.00